Search

Lakshmi Bhagat

from Framingham, MA
Age ~62
Get Report
Also known as:
Laxmi Bhagat, Bhagat Bhagat
Phone and address:
1550 Worcester Rd, Framingham, MA 01702
(508) 875-9841
Connected to:
Alisha N Bhagat, 42Amrita N Bhagat, 48Anand A Bhagat, 29Anita M Bhagat, 65Dicky G Bhagat, 63Dilip H Bhagat, 69Gemini D Bhagat, 75Govind K Bhagat, 81Haresh G Bhagat, 79Hemendra V Bhagat, 41

Lakshmi Bhagat Phones & Addresses

  • 1550 Worcester Rd, Framingham, MA 01702 (508) 875-9841
  • 1550 Worcester Rd UNIT 605, Framingham, MA 01702 (508) 875-9841
  • 17 Fairbanks St, Brookline, MA 02446 (617) 566-0922

Publications

Us Patents

Short Immunomodulatory Oligonucleotides

View page
US Patent:
7354907, Apr 8, 2008
Filed:
Feb 7, 2003
Appl. No.:
10/361111
Inventors:
Sudhir Agrawal - Shrewsbury MA, US
Ekambar R. Kandimalla - Southboro MA, US
Dong Yu - Westboro MA, US
Lakshmi Bhagat - Brookline MA, US
Assignee:
Idera Pharmaceuticals, Inc. - Cambridge MA
International Classification:
C07H 21/02
C07H 21/00
C07H 21/04
A01N 43/04
A61K 31/70
US Classification:
514 44, 514 45, 514 46, 514 47, 514 48, 536 231, 536 251, 536 253, 536 256
Abstract:
The invention relates to modulation of the immune system. More particularly, the invention relates to modulating the immune system through the use of oligonucleotide-derived compounds. The invention provides immunostimulatory agents that are less expensive to make than existing immunostimulatory oligonucleotides. The immunostimulatory agents according to the invention can, in preferred embodiments, cause immune stimulation across species lines.

Modulation Of Immunostimulatory Properties Of Oligonucleotide-Based Compounds By Optimal Presentation Of 5′ Ends

View page
US Patent:
7407944, Aug 5, 2008
Filed:
Aug 25, 2004
Appl. No.:
10/925872
Inventors:
Sudhir Agrawal - Shrewsbury MA, US
Ekambar R. Kandimalla - Southboro MA, US
Dong Yu - Westboro MA, US
Lakshmi Bhagat - Brookline MA, US
Assignee:
Idera Pharmaceuticals, Inc. - Cambridge MA
International Classification:
A61K 31/70
A61K 38/00
A61K 38/16
A61K 39/00
A61K 39/35
A61K 39/38
A61K 39/12
A61K 39/02
A61K 39/002
A61K 45/00
A61K 47/00
A01N 43/04
A01N 37/18
C07H 21/02
C07H 21/04
US Classification:
514 44, 514 48, 514 2, 514 8, 514 45, 514 46, 514 47, 4241841, 4242341, 4242041, 4242651, 4242741, 4242781, 4242771, 4242751, 536 231
Abstract:
The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers of the invention comprise at least two oligonucleotides linked at their 3′ ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunostimulatory oligonucleotide and having an accessible 5′ end.

Modulation Of Immunostimulatory Properties Of Oligonucleotide-Based Compounds By Optimal Presentation Of 5′ Ends

View page
US Patent:
7517862, Apr 14, 2009
Filed:
Aug 25, 2004
Appl. No.:
10/925873
Inventors:
Sudhir Agrawal - Shrewsbury MA, US
Ekambar R. Kandimalla - Southboro MA, US
Dong Yu - Westboro MA, US
Lakshmi Bhagat - Brookline MA, US
Assignee:
Idera Pharmaceuticals, Inc. - Cambridge MA
International Classification:
A01N 43/04
A61K 31/70
A61K 39/395
A61K 39/00
A61K 39/38
A61K 39/12
A61K 39/002
A61K 39/02
A61K 39/35
A61K 39/36
A61K 47/00
US Classification:
514 44, 514 45, 514 46, 514 47, 514 48, 4241841, 4242341, 4241411, 4241301, 4242781, 4242651, 4242771, 4242751, 4242041
Abstract:
The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers of the invention comprise at least two oligonucleotides linked at their 3′ ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunostimulatory oligonucleotide and having an accessible 5′ end.

Synergistic Treatment Of Cancer Using Immunomers In Conjunction With Therapeutic Agents

View page
US Patent:
7569554, Aug 4, 2009
Filed:
May 14, 2004
Appl. No.:
10/846167
Inventors:
Ekambar R. Kandimalla - Southboro MA, US
Sudhir Agrawal - Shrewsbury MA, US
Daqing Wang - Bedford MA, US
Lakshmi Bhagat - Framingham MA, US
Dong Yu - Westboro MA, US
Assignee:
Idera Pharmaceuticals, Inc. - Cambridge MA
International Classification:
A61K 39/395
A61K 31/7105
A61K 31/7115
A61K 31/7125
US Classification:
514 44, 4241301, 4241561
Abstract:
The invention relates to the therapeutic use of immunostimulatory oligonucleotides and/or immunomers in combination with chemotherapeutic agents to provide a synergistic therapeutic effect.

Modulation Of Immunostimulatory Properties Of Oligonucleotide-Based Compounds By Utilizing Modified Immunostimulatory Dinucleotides

View page
US Patent:
7595305, Sep 29, 2009
Filed:
Jul 1, 2005
Appl. No.:
11/173794
Inventors:
Sudhir Agrawal - Shrewsbury MA, US
Lakshmi Bhagat - Framingham MA, US
Dong Yu - Westboro MA, US
Ekambar Kandimalla - Southboro MA, US
Assignee:
Idera Pharmaceuticals - Cambridge MA
International Classification:
C07H 21/02
C07H 21/04
A01N 43/04
A61K 31/70
US Classification:
514 44, 514 45, 536 231
Abstract:
The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers and an immunostimulatory oligonucleotides for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers and an immunostimulatory oligonucleotides of the invention preferably comprise novel purines. The immunomers according to the invention further comprise at least two oligonucleotides linked at their 3′ ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunomodulatory oligonucleotide and having an accessible 5′ end.

Modulation Of Immunostimulatory Properties Of Oligonucleotide-Based Compounds By Utilizing Modified Immunostimulatory Dinucleotides

View page
US Patent:
7632822, Dec 15, 2009
Filed:
Jul 1, 2005
Appl. No.:
11/173938
Inventors:
Sudhir Agrawal - Shrewsbury MA, US
Lakshmi Bhagat - Framingham MA, US
Dong Yu - Westboro MA, US
Ekambar Kandimalla - Southboro MA, US
Assignee:
Idera Pharmaceuticals, Inc. - Cambridge MA
International Classification:
C07H 21/02
C07H 21/04
A01N 43/04
A61K 31/70
US Classification:
514 44, 514 45, 536 231
Abstract:
The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers and an immunostimulatory oligonucleotides for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers and an immunostimulatory oligonucleotides of the invention preferably comprise novel purines. The immunomers according to the invention further comprise at least two oligonucleotides linked at their 3′ ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunomodulatory oligonucleotide and having an accessible 5′ end.

Modulation Of Immunostimulatory Properties Of Oligonucleotide-Based Compounds By Optimal Presentation Of 5′ Ends

View page
US Patent:
7749975, Jul 6, 2010
Filed:
Jul 1, 2005
Appl. No.:
11/174450
Inventors:
Sudhir Agrawal - Shrewsbury MA, US
Ekambar R. Kandimalla - Southboro MA, US
Dong Yu - Westboro MA, US
Lakshmi Bhagat - Brookline MA, US
Assignee:
Idera Pharmaceuticals, Inc. - Cambridge MA
International Classification:
C07H 21/02
C07H 21/04
A61K 39/38
A61K 39/00
A61K 39/395
A61K 45/00
A61K 47/00
US Classification:
514 44, 514 45, 514 46, 514 47, 514 48, 4241301, 4241841, 4242781
Abstract:
The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers of the invention comprise at least two oligonucleotides linked at their 3′ ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunostimulatory oligonucleotide and having an accessible 5′ end.

Modulation Of Immunostimulatory Properties Of Oligonucleotide-Based Compounds By Optimal Presentation Of 5′ Ends

View page
US Patent:
7812000, Oct 12, 2010
Filed:
Oct 3, 2007
Appl. No.:
11/906781
Inventors:
Sudhir Agrawal - Shrewsbury MA, US
Ekambar R. Kandimalla - Southboro MA, US
Dong Yu - Westboro MA, US
Lakshmi Bhagat - Framingham MA, US
Assignee:
Idera Pharmaceuticals, Inc. - Cambridge MA
International Classification:
C07H 21/04
C07H 21/02
A01N 43/04
A61K 39/00
A61K 39/38
A61K 45/00
A61K 47/00
A61K 31/70
US Classification:
514 44R, 514 45, 514 46, 514 47, 514 48, 536 231, 4241841, 4242781
Abstract:
The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers of the invention comprise at least two oligonucleotides linked at their 3′ ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunostimulatory oligonucleotide and having an accessible 5′ end.
Control profile
Lakshmi Bhagat from Framingham, MA, age ~62 Get Report